Alpha adrenergic and serotonergic agents in the treatment of spastic hypertonia

Physical Medicine and Rehabilitation Clinics of North America

Volumn 12, Issue 4, 2001, Pages 889-905

  Nance, P W ^a  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BACLOFEN; CARISOPRODOL; CHLORPHENESIN CARBAMATE; CHLORPROMAZINE; CHLORZOXAZONE; CLONIDINE; CYCLOBENZAPRINE; CYPROHEPTADINE; DANTROLENE; DEXMEDETOMIDINE; DIAZEPAM; DIXIRIT; DRONABINOL; METAXALONE; METHOCARBAMOL; NABILONE; ROBAMOL; SEROTONIN RECEPTOR; TIZANIDINE;

DOSE CALCULATION; DRUG ABSORPTION; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; HUMAN; MUSCLE HYPERTONIA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; SPASTICITY; TITRIMETRY; TREATMENT PLANNING;

EID: 0035149935     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1047-9651(18)30037-8     Document Type: Review

References (129)

1. Tizanidine-induced toxic hepatitis
2. A study of the adrenotropic receptors
3. Cyproheptadine in treatment of chronic schizophrenia: A double-blind, placebo-controlled study
4. Tizanidine protects mice against convulsions induced by lidocaine: Involvement of alpha 2-adrenoceptors
5. Effect of large mesencephalic-diencephalic lesions on the noradrenalin, dopamine and 5-hydroxytryptamine neurons of the central nervous system
6. Effective prophylactic therapy for cyclic vomiting syndrome in children using amitriptyline or cyproheptadine
7. Spasticity: Current and future management
8. Antinociception by epidural and systemic alpha2adrenoceptor agonists and their binding affinity in rat spinal cord and brain
9. Preliminary trial of carisoprodol in multiple sclerosis
10. Action of cyproheptadine in spastic paraparetic patients
11. Tizanidine is an effective agent in the prevention of focal cerebral ischemia in rats: An experimental study
12. Tizanidine and ibuprofen in acute low-back pain: Results of a double-blind multicentre study in general practice
13. Dexmedetomidine
14. Does methocarbamol affect fatigue markers in the low-back electromyogram?
15. Tranquilizers: I. phenothiazine derivatives
16. An approach to switching patients from baclofen to tizanidine
17. Fourth International Union of Pharmacology nomenclature of adrenoceptors
18. Risk factors for severe bradycardia during oral clonidine therapy for hypertension
19. Spinal pharmacology of tactile allodynia in diabetic rats
20. The adrenergic agonist tizanidine has differential effects on flexor reflexes of intact and spinalized rat
21. Cyproheptadine treatment of nightmares associated with posttraumatic stress disorder
22. Tetrahydrocannabinol for tremor in multiple sclerosis
23. Phenytoin and chlorpromazine in the treatment of spasticity
24. Cyproheptadine produced modest increases in total caloric intake by humans
25. Tizanidine-induced depression of polysynaptic cutaneous reflexes in nonanaesthetized monkeys is mediated by an a2-adrenergic mechanism
26. Pharmacological properties of tizanidine (DS103-282)
27. Tizanidine: Neuropharmacology and mechanism of action
28. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons
29. The use of sirdalud in painful muscle tonic syndromes
30. Tizanidine (DS103-282), a centrally acting muscle relaxant, selectively depresses excitation of feline dorsal horn neurones to noxious peripheral stimuli by an action at alpha adrenoceptors
31. Selective antinociceptive effects of tizanidine (DS 103-282), a centrally acting muscle relaxant, on dorsal horn neurones in the feline spinal cord
32. Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-choloro-4-(2-imidazolin-2-yl-amino)-2, 1, 3-benzothiadiazole (DS103 282)
33. A review of carisoprodol deaths in Jefferson County, Alabama
34. Electrophysiological testing of spastic patients: Its potential usefulness and limitations
35. Trigeminal neuralgia. New treatment options for a well-known cause of facial pain
36. The effect of tizanidine on maximal electroshock seizures (MES) in mice
37. Clonidine effect on spasticity: A clinical trial
38. Hallucinations in an elderly patient taking recommended doses of cyclobenzaprine
39. The perceived effects of marijuana on spinal cord injured males
40. Review of clinical trials with Sirdalud in spasticity
41. Scopolamine-inducedconvulsions in food given fasted mice: Effects of clonidine and tizanidine
42. Diffuse cutaneous mastocytosis responding to cyproheptadine
43. 1-imidazoline sites
44. The treatment of tension headache with sirdalud
45. 3H]mivazerol binds to non-adrenergic binding sites in human striatum membranes that are distinct from imidazoline receptors
46. Transmitters involved in antinociception in the spinal cord
47. A search for presynaptic imidazoline receptors at rabbit and rat noradrenergic neurones in the absence of alpha 2-autoinhibition
48. The serotonin syndrome and its treatment
49. Effects of the selective I1 imidazoline receptor agonist, moxonidine, on gastric secretion and gastric mucosal injury in rats
50. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments
51. Treatment of the serotonin syndrome with cyproheptadine
52. Nightmares treated with cyproheptadine
53. Sedative, amnestic, and analgesic properties of smalldose dexmedetomidine infusions
54. Selective reduction by noradrenaline and 5-hydroxytryptamine of nociceptive responses of cat dorsal horn neurones
55. Alterations in synaptic input to motoneurons during partial spinal cord injury
56. Evidence for the existence of imidazoline-specific binding sites in synaptosomal plasma membranes of the bovine brainstem
57. Possible structural and functional relationships between imidazoline receptors and alpha 2-adrenoceptors
58. Dopaminergic agonists differentially affect open-field activity of rats with A10 lesions
59. Cyproheptadine for serotonin syndrome in an accidental pediatric sertraline ingestion
60. Modulation of responses of feline gamma-motoneurones by noradrenaline, tizanidine and clonidine
61. Monoaminergic inhibitory control of spinal interneurons
62. Analysis of the effects of p-methoxy-phenylethylamine on spinal cord neurones
63. Antinociceptive action of tizanidine in mice and rats
64. Antinociceptive interaction of intrathecal alpha2-adrenergic agonists, tizanidine and clonidine, with lidocaine in rats
65. Spinalization unmasks clonidine's alpha-1 adrenergic mediated excitation of the flexor reflex in rats
66. Alpha-2 and imidazoline receptor agonist their pharmacology and therapeutic role
67. Quantitative autoradiographic localization in rat brain of alpha 2-adrenergic and non-adrenergic I-receptor binding belled by [3H]rilmenidine
68. Drugs used to treat spasticity
69. Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis
70. Investigations into the mechanisms of the hypotensive effect of 2,(2,6-dichlorophenylamino)2-imidazoline HCl
71. Imidazoline binding sites in fat cells. Localization and pharmacologic diferentiation from alpha 2-adrenergic receptors
72. Comparative profile of tizanidine in the management of spasticity
73. The imidazoline-preferring receptor
74. Persistent failure-to-thrive: A case study
75. A cyproheptadine fatality
76. Alpha 2-adrenergic, but not imidazole, agonists NaCl cotransport in rabbit tracheal epithelial cells
77. Carisoprodol, meprobamate, and driving impairment
78. Double-blind cross-over dose titration on the safety and efficacy of tizanidine for spastic hypertonia due to acquired brain injury
79. Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: A case study
80. Central catecholamine neuron systems: Anatomy and physiology of the norepinephrine and epinephrine systems
81. Imidazoline receptors. Historic review and current status of knowledge
82. Imidazoline binding sites and signal transduction pathways
83. Changes in the CNS biogenic amines and tyrosine hydroxylase activity after spinal cord transection in the rat
84. A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients
85. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury
86. Reflex changes induced by clonidine in spinal cord injured patients
87. Clonidine in spinal cord injury
88. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis
89. Pharmacology of descending noradrenergic systems in relation to motor function
90. On the preparation of the Indian hemp or ganja
91. Importance of the locus coeruleus and imvolvement of alpha-adrenergic receptors in the post-decapitation reflex in the rat
92. Central and renal I1 imidazoline preferring receptors: Two unique sites mediating natriuresis in the rat
93. Effects of tizanidine administration on precipitated opioid withdrawal signs in rats
94. Effects of local injection of the a2-adrenergic agonist clonidine into the locus coeruleus complex on the gain of vestibulospinal and cervicospinal reflexes in decerebrate cats
95. Effects of acute dorsal spinalion on motomeuron discharge in the medial gastrocnemius of the decerebrate cat
96. Carisoprodol (soma): Abuse potential and physician unawareness
97. Use of carisoprodol by substance abusers to modify the effects of illicit drugs
98. Chronic treatment with dexmedetomidine desensitizes alpha2-adrenergic signal transduction
99. On the therapeutic uses and toxic effects of cannabis indica
100. Dexmedetomidine, diazepam, and propanolol in the treatment of ethanol withdrawal symptoms in the rat
101. Flumazenil reversal of carisoprodol (Soma) intoxication
102. Carisoprodol-induced myoclonic encephalopathy
103. Immunocytochemical localization of an imidazoline receptor protein in the central nervous system
104. The pharmacology of 5-chloro-4-(2-imidazolin2-yl-amino)-2,1,3-benzothiadiazole (DS 103 282), a novel myotonolytic agent
105. Pain reduction in breast augmentation using methocarbamol
106. The effect of DOPA and clonidine on reflex pathways from group II afferents to alpha-motoneurons in the cat
107. Use of cyproheptadine to control urine spraying in a castrated male domestic cat
108. A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state
109. A comparison of the effects of two antispastic drugs, tizanidine and baclofen, on synaptic transmission from muscle spindle afferents to spinal interneurons in cats
110. Muscle relaxant activity of methocarbamol enantiomers in mice
111. Preferential blockade of presynaptic alpha-adrenoceptors by yohimbine
112. The treatment of spasticity in multiple sclerosis: A double-blind clinical trial of a new anti-spasticity drug tizanidine compared with baclofen
113. Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine
114. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery
115. Distribution of alpha-2 agonist binding sites in the rat and human central nervous system
116. The treatment of the phantom pain syndrome with tizanidine
117. The nitric oxide-CGMP system of the locus ceruleus the hypnotic action of alpha-2 adrenergic agonists
118. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders
119. Modulatory action of cyproheptadine on the locomotor pattern of spastic paretic patients
120. Clonidine transdermal system for treatment of spasticity in spinal cord injury
121. Organization of descending noradrenergic systems
122. Pharmacological antagonism of facilitatory but not inhibitory effects of serotonin and norepinephrine on excitability of spinal motoneurons
123. Noradrenergic mechanisms involved in muscle relaxation: Significance for the treatment of spasticity
124. Effect of transdermal clonidine on spinal spasticity: A case series
125. 2-adrenergic agonist, blunts cardiovascular effects following surgical stress in pentobarbital-anesthetized rats